HER2 Low Metastatic

Advertisement
Sara Nunnery, MD, MSCIHER2 Breast Cancer | April 24, 2025
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Read More
Sara Nunnery, MD, MSCIHER2 Breast Cancer | April 22, 2025
Dr Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Brandon TwyfordHER2 Breast Cancer | April 4, 2025
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Brianna GrahamHER2 Breast Cancer | April 3, 2025
Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends.
Brianna GrahamHER2 Breast Cancer | April 2, 2025
A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.
Brandon TwyfordHER2 Breast Cancer | April 2, 2025
Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.
Leah LawrenceHER2 Breast Cancer | March 31, 2025
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
Leah LawrenceHER2 Breast Cancer | March 31, 2025
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Nera Lopetegui-Lia, MDHER2 Breast Cancer | March 31, 2025
Dr. Lopetegui-Lia reacts to Dr. Gatti-Mays' breast cancer panel discussion from Advancements in Oncology.
Dr. Margaret Gatti-MaysHER2 Breast Cancer | March 31, 2025
Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.
Rob DillardHER2 Breast Cancer | March 31, 2025
Dr. Margaret Gatti-Mays talks with The Oncology Brothers about the right treatments for endocrine-resistant breast cancer.
Advertisement
Advertisement
Latest News

April 25, 2025